This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.
February 2024 in “International Journal of Molecular Sciences” This review outlines the functional anatomy, pathology, and molecular mechanisms of androgenetic alopecia, emphasizing the need for multi-omics approaches to better understand this condition's biology.
January 2024 in “Journal of Education, Health and Sport” This review discusses the potential benefits of platelet-rich plasma (PRP) for treating androgenic alopecia in athletes and examines how physical activity might influence androgen levels, but it reports no new results.
November 2023 in “International Journal of Medical Sciences” This review examines the mechanisms of hair follicle development and regeneration, discussing current hair loss treatments and emerging therapies like low-level laser therapy and stem cell therapy, which the authors suggest show promise in managing hair loss.
August 2023 in “Stem Cell Research & Therapy” This study found that cell-free fat extract (CEFFE) enhanced hair growth in mice with androgenetic alopecia by increasing hair follicle density and promoting proliferation while regulating the DHT/AR pathway.
August 2023 in “Drug Design Development and Therapy” This study found that minoxidil may treat androgenetic alopecia by affecting hormonal and enzymatic pathways, identifying new targets CYP17A1 and CYP19A1 and demonstrating its inhibition of androgenic receptors.
June 2023 in “Stem cell reviews and reports” This review summarizes current methods, effectiveness, and clinical progress of stem cell therapies for androgenetic alopecia, highlighting their potential for hair regrowth and follicle repair despite unclear long-term effects and mechanisms.
June 2023 in “Skin Research and Technology” The researchers reported that an oral supplement containing hydrolysed fish-origin collagen, taurine, cysteine, methionine, iron, and selenium significantly improved the effectiveness of anti-hair loss treatments in people with androgenic alopecia or chronic telogen effluvium after 12 weeks, compared to drug treatments alone.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
April 2023 in “Nigerian Journal of Clinical Practice” In this study, androgenetic alopecia in Nigerians was associated with dyslipidemia, alcohol intake, and sedentary lifestyle, with severity linked to age, systolic blood pressure, and obesity.
March 2023 in “Anais Brasileiros De Dermatologia” This article reviews treatment options for female-pattern hair loss, noting the limited evidence for most therapies and emphasizing that topical minoxidil remains the only well-supported option despite a significant non-response rate.
This review suggests that stem cells might be a promising addition or alternative to standard treatments for androgenic alopecia, but larger studies are needed to confirm these findings.
March 2023 in “Advances in Clinical and Experimental Medicine” This systematic review concluded that 5 mg of oral finasteride per day could be an effective and safe treatment for female pattern hair loss in normoandrogenic women, particularly when combined with other medications.
This study identified CXXC5 as a key mediator of hair loss induced by PGD2 and DHT via suppression of the Wnt/β-catenin pathway, with implications for potential therapeutic targets.
2 citations
,
January 2023 in “International Journal of Biological Sciences” In this study, miR-221 was identified as a key factor in androgenetic alopecia pathogenesis due to its role in suppressing hair growth by interacting with androgen receptors and affecting related pathways.
January 2023 in “Dermatology” This review summarizes biological links between aging and androgenetic alopecia, particularly focusing on cellular senescence, and discusses potential therapeutic strategies, but reports no new clinical results.
1 citations
,
January 2023 in “PubMed” This systematic review and meta-analysis found limited, low-quality evidence suggesting that platelet-rich plasma injections may increase hair density in patients with androgenetic alopecia compared to saline, but results were inconclusive for alopecia areata.
December 2022 in “Archives of Dermatological Research” This study found that topical cetirizine increased hair shaft thickness and improved clinical outcomes from the patients' perspective in female androgenetic alopecia compared to minoxidil alone, with similar side effect profiles.
November 2022 in “Molecular Pharmaceutics” This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.
October 2022 in “Journal of Dermatological Treatment” This study found that autologous platelet-rich plasma injections may improve terminal hair density in women with androgenetic alopecia, but did not significantly affect hair thickness.
1 citations
,
July 2022 in “British Journal of Dermatology” In this study, researchers identified key transcriptome changes in male androgenetic alopecia hair follicles, suggesting that HIF-1 pathway genes and Wnt pathway inhibitors could be potential therapeutic targets.
1 citations
,
April 2022 in “Journal of Cosmetic Dermatology” This review highlights that androgenetic alopecia significantly impacts psychological well-being and quality of life, emphasizing the need for integrated psychological support alongside dermatological treatment.
18 citations
,
March 2022 in “Drug design, development and therapy” This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.
13 citations
,
February 2022 in “JAMA Dermatology” This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.
6 citations
,
January 2022 in “Journal of Investigative Dermatology” This study found that androgen receptor signaling is linked to blood vessel regression in the dermal papilla of balding scalp, contributing to hair follicle miniaturization in androgenetic alopecia.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.
7 citations
,
April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences” This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.
8 citations
,
March 2021 in “Medicina-lithuania” This review discusses the use of platelet-rich plasma for treating female androgenetic alopecia, reporting that it shows high patient satisfaction and improved quality of life in affected women.
3 citations
,
January 2021 in “Medicinski arhiv” In this study, trichoscopic examination revealed that patients with androgenetic alopecia had significantly more yellow dots, pilosebaceous units with one hair, and increased perifollicular hyperpigmentation compared to healthy controls.
6 citations
,
October 2020 in “Actas Dermo-Sifiliográficas” This review discusses the effectiveness of low-level laser therapy for androgenetic alopecia, finding significant increases in hair density and growth for individuals treated with this method.
13 citations
,
September 2020 in “International Journal of Molecular Sciences” This study found that combining platelet-rich plasma therapy with minoxidil was more effective in treating androgenetic alopecia in men than either treatment alone.
86 citations
,
July 2020 in “International Journal of Molecular Sciences” This review discusses the role of Wnt/β-catenin signaling in hair follicle regeneration and highlights recent progress in developing hair loss treatments targeting this pathway, but reports no new clinical results.
12 citations
,
May 2020 in “Actas Dermo-Sifiliográficas” This article discusses emerging therapies for androgenetic alopecia, highlighting the use of intradermal dutasteride, but it reports no new clinical findings.
65 citations
,
April 2020 in “International Journal of Molecular Sciences” This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.
59 citations
,
March 2020 in “Journal of Biomedical Science” This study explored the complex roles of niche cells in regulating hair follicle stem cells, identifying specific cell functions such as signaling, sensing, and relaying messages, which could provide insights into treating hair loss conditions like androgenetic alopecia and alopecia areata.
32 citations
,
March 2020 in “Drug Design Development and Therapy” This review examines the pharmacology, clinical efficacy, and adverse effects of oral finasteride for female pattern hair loss, and discusses potential new treatments like topical finasteride and dutasteride, but reports no new clinical results.
5 citations
,
January 2020 in “Skin appendage disorders” This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.
15 citations
,
January 2020 in “BioMed Research International” In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.
8 citations
,
January 2020 in “Skin Pharmacology and Physiology” This article discusses the potential for topical caffeine as a natural alternative for treating androgenetic alopecia due to its ability to penetrate skin, but it reports no new clinical findings.
30 citations
,
January 2020 in “Fertility and Sterility” This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
25 citations
,
September 2019 in “PubMed” This review discusses the therapeutic potential of platelet-rich plasma in dermatology and highlights the need for standardized treatment protocols, but reports no new clinical results.
117 citations
,
August 2019 in “Drug Design Development and Therapy” This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.
38 citations
,
February 2019 in “Clinical Interventions in Aging” This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.
15 citations
,
January 2018 in “Acta dermato-venereologica” This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.
